Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms 44Sc-labeled DOTA-NAPamide, Sc-44-labeled DOTA-NAPamide |
Target |
Action modulators, enhancers |
Mechanism MC1R modulators(Melanocortin receptor 1 modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma | Preclinical | Hungary | 16 Jun 2017 |





